Atara Biotherapeutics Reports Exit/Disposal Costs

Ticker: ATRA · Form: 8-K · Filed: Mar 3, 2025 · CIK: 1604464

Atara Biotherapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyAtara Biotherapeutics, INC. (ATRA)
Form Type8-K
Filed DateMar 3, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: restructuring, disposal, financial-reporting

Related Tickers: ATRA

TL;DR

ATRA filed an 8-K for exit/disposal costs - watch for financial impact.

AI Summary

On March 3, 2025, Atara Biotherapeutics, Inc. filed an 8-K report detailing cost associated with exit or disposal activities. The filing does not specify dollar amounts or exact dates for these activities, but it indicates a formal reporting of these financial events.

Why It Matters

This filing signals potential restructuring or divestiture activities within Atara Biotherapeutics, which could impact its operational focus and financial future.

Risk Assessment

Risk Level: medium — Reporting exit or disposal costs can indicate significant business changes, which may carry financial and operational risks.

Key Players & Entities

FAQ

What specific activities are associated with the exit or disposal costs reported by Atara Biotherapeutics?

The filing does not provide specific details on the nature of the exit or disposal activities, only that costs are associated with them.

When did the earliest event related to these exit or disposal costs occur?

The earliest event reported in this 8-K filing occurred on March 03, 2025.

What is the primary business of Atara Biotherapeutics, Inc.?

Atara Biotherapeutics, Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code.

Where are Atara Biotherapeutics, Inc.'s principal executive offices located?

The principal executive offices are located at 1280 Rancho Conejo Blvd, Thousand Oaks, California, 91320.

What is the Commission File Number for Atara Biotherapeutics, Inc.?

The Commission File Number for Atara Biotherapeutics, Inc. is 001-36548.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 3, 2025 regarding Atara Biotherapeutics, Inc. (ATRA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing